miraDry’s 34% Patient-Spending Surge: Is the Outperformance Already in the Price?

The numbers for miraDry in 2025 are a clear beat against the broader market. In the final quarter of the year, total patient spending on the treatment grew by 34% year-over-year. That pace was more than 10 times faster than the overall energy-based device (EBD) category, which itself is a large and growing market. The EBD sector was valued at $7.03 billion in 2025 and is projected to grow at a compound annual rate of 9-18% through the 2030s.

This isn't just a category outperformance; it's a statement about the treatment's positioning. miraDry's growth is driven by a fundamental shift in perception. The company attributes its momentum to increasing awareness of sweat and odor reduction as an important quality-of-life treatment, moving beyond the traditional cosmetic lens. This reframing taps into a significant, underserved need, with as many as 33% of people reporting excessive sweating that impacts their daily lives.

The bottom line is that miraDry delivered a spectacular growth print in 2025, far outstripping its peers. For an investor, the critical question now is whether this massive outperformance was already fully priced into the stock, setting the stage for a potential expectation gap in the year ahead.

The Whisper Number vs. The Print

The market's whisper number for miraDry in 2025 was likely already high. The company's own recognition of top-performing providers suggests the momentum was visible and acknowledged well before the final numbers were in. This isn't a surprise catalyst; it's the culmination of a strategy that was working. The 34% growth in patient spending is a massive beat against the broader category, but the real question is whether that beat was already baked into the stock price.

Viewed through the lens of the entire energy-based aesthetic devices market, miraDry's performance looks more like a function of its niche dominance than a pure outperformance. The market itself is a powerhouse, projected to grow at a CAGR of 9.02% through 2031 and valued at $7.03 billion in 2025. Even more aggressively, another report forecasts a CAGR of 17.9% to 2034. In this context, miraDry's 34% growth, while impressive, may be seen as the natural result of a leader capturing a disproportionate share of a rapidly expanding pie. The market may have priced in the expectation that the category leader would grow faster than the average.

The key risk now is a guidance reset. If future growth rates moderate toward the broader market's 9-18% range, it could disappoint investors who bought the rumor of sustained, outsized acceleration. The "beat and raise" dynamic of 2025 has set a high bar. The company's strong provider partnerships and patient awareness efforts are real, but they may now be the baseline expectation. The expectation gap isn't about whether miraDry will grow-it's about whether it can keep growing at a rate that surprises the consensus. For now, the outperformance is real, but the market may have already bought it.

Catalysts and Risks: The Path to Sustained Outperformance

The path forward for miraDry is a clear game of expectation arbitrage. The company's primary catalyst is its plan to expand its provider network across North America. This move is designed to drive patient access and spending growth, directly addressing the next leg of its growth story. By onboarding more providers, miraDry aims to convert the growing awareness of its treatment into broader commercial scale. If executed well, this network build-out could widen the expectation gap, proving the company can sustain its outperformance beyond its current base of top-tier partners.

Yet the path is not without friction. The key risk is competition from other energy-based devices in the $5-7 billion market. While miraDry holds a unique position for underarm sweat and odor, the broader category is crowded with players like Bausch Health and Cutera. If these competitors develop or market competing sweat/odor solutions, it could pressure pricing or market share. The expectation gap could close quickly if the market perceives miraDry's dominance as less durable than its clinical claims suggest.

Ultimately, the company's success hinges on maintaining its core value proposition: permanent reduction. This claim is supported by clinical studies showing long-term efficacy, which is critical for patient education and trust. But the burden of proof is ongoing. miraDry must continuously demonstrate that its microwave technology delivers a lasting solution that alternatives cannot match. In a market where minimally invasive treatments are in demand, the permanence of the result is the ultimate differentiator. For now, the catalyst is clear-expand the network. The risk is competition. The outcome depends on whether the company can keep its clinical promise ahead of the market's growing expectations.